Loading
NASDAQHealthcareBiotechnology
Latest quote
$53.25
−$1.29 · -2.37%
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Latest quote
$53.25
−$1.29 · -2.37%
After-hours
$53.25
$0.00 · 0.00%
Oct 8, 4:43 PM ET
Regular session · ET · Market data may be delayed.
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Day range
Current $53.25
52-week range
Current $53.25
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
55
Mixed
Risk
39
Moderate Risk
Momentum
81
Strong Up
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Day range
Current $53.25
52-week range
Current $53.25
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cost of goods sold | 248K USD | — | — | — |
| Gross profit | −248K USD | — | — | — |
| Research and development | 79.16M USD | 57.42M USD | 28.53M USD | 21.4M USD |
| Selling, general, and administrative | 18.9M USD | 10.78M USD | 6.78M USD | 3.76M USD |
| Operating expenses | 98.06M USD | 68.19M USD | 35.31M USD | 25.16M USD |
| Interest income | 11.08M USD | 6.27M USD | 2.75M USD | 372K USD |
| Interest expense | — | — | — | 374K USD |
| Depreciation and amortization | 248K USD | 244K USD | 157K USD | 56K USD |
| Operating income | −98.06M USD | −68.19M USD | −35.31M USD | −25.16M USD |
| Net income | −86.97M USD | −61.92M USD | −32.56M USD | −26.14M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$94.40
77.28% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI70.12M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM44.56M0.06%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF19.04M0.02%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO15.85M0.11%14.25B USD0.24%$353.47-0.53%
iShares Biotechnology ETFIBB12.59M0.12%10.4B USD0.44%$200.48-1.41%
Vanguard Russell 2000 ETFVTWO10.99M0.06%18B USD0.06%$112.1-0.10%
Schwab U.S. Small-Cap ETFSCHA8.6M0.04%21.7B USD0.03%$32.66+0.15%
Fidelity Enhanced Small Cap ETFFESM8.28M0.13%6.41B USD0.28%$45.25+0.07%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
